NCT Number: NCT06200103
Phase: PHASE2
Trial Summary: This phase IV studies how to improve the use of Lu 177 vipivotide tetraxetan (177Lu-prostate-specific membrane antigen [PSMA]-617) for treating patients with castration-resistant prostate cancer tha – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Mayo Clinic
Acronym:
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives